Axis Reimbursement Expands Operations into United States
The healthcare consultancy firm officially entered the US market in June 2026 to support pharmaceutical clients.
Updated on Oct. 30, 2026 in Healthcare
Live Poll
Do you trust small consulting firms to navigate the complexities of international healthcare markets successfully?
Axis Reimbursement, a firm that assists pharmaceutical companies with reimbursement schemes, expanded its operations into the United States in June 2026. This move follows the company's previous international growth into the UK market in 2023.
Why it matters
The expansion aims to facilitate broader international market access for pharmaceutical companies by helping them demonstrate the clinical and cost-effectiveness of their products. This strategic shift positions the firm to support clients navigating diverse state reimbursement requirements.
Axis Reimbursement generated €3.3 million in revenue in 2025 and currently employs 20 permanent staff alongside 10 contractors. The firm holds 6 percent of the UK market share and projects total revenue to reach €5 million by the end of 2026.
The players
Axis Reimbursement
This Dublin-based firm specializes in helping pharmaceutical companies prove the cost-effectiveness of products for state reimbursement.
Enterprise Ireland
This is the Irish government organization responsible for the development and growth of Irish enterprises in world markets.
Brenda Dooley
She is the founder of Axis Reimbursement who established the company in 2011.
The details
The firm provides technical support to help pharmaceutical companies navigate complex state reimbursement schemes. Enterprise Ireland provided essential office space and trade show support to facilitate this international expansion.
Timeline
Brenda Dooley founded the firm in 2011.
The business began experiencing significant growth in 2018.
The firm officially expanded its reach into the United Kingdom in 2023.
The company entered the United States market in June 2026.
The firm projects an annual revenue of €5 million for the 2026 fiscal year.
Market Landscape
The firm's expansion follows the documented trend of the rise of global specialized market access consultancies as pharmaceutical firms seek to streamline regional regulatory navigation. This strategy allows the company to compete by leveraging regional expertise against larger, generic consultancy firms.
While this expansion is corporate in nature, clients and healthcare stakeholders can expect increased support for evidence-based reimbursement strategies in the US market. The company's growth may influence how quickly certain pharmaceutical products secure access to regional health schemes.
The takeaway
The move highlights the increasing importance of specialized firms in navigating complex global healthcare reimbursement requirements. Pharmaceutical companies are likely to continue prioritizing partnerships that can provide granular data on cost-effectiveness in diverse regulatory environments.
Further reading
Learn more about the latest industry movements in Healthcare.
Source note: This article includes information reported by Business Post.
Live Poll
Do you trust small consulting firms to navigate the complexities of international healthcare markets successfully?
